Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 16,277 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Condition Clear all
Active, not recruiting No phase listed Observational

Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

NCT03281902
View directory record Official record
Conditions
Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 23, 2026, 4:20 AM EDT
Completed Phase 2 Interventional Results available

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

NCT00923195
View directory record Official record
Conditions
Melanoma, Skin Cancer
Interventions
MART-1: 26-35(27L) Peptide, Montanide ISA 51 VG, gp100:154-162 Peptide, Radiation, Aldesleukin, Fludarabine, Cyclophosphamide, Anti-gp 100:154 TCR PBL, Anti-MART-1 F5 TCR PBL
Drug · Procedure · Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 23, 2026, 4:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome

NCT03789175
View directory record Official record
Conditions
Cancer, Skin Fibroblasts, Muscle Weakness
Interventions
Nicotinamide Riboside (NR)
Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 23, 2026, 4:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis

NCT06742957
View directory record Official record
Conditions
Plaque Type Psorisis
Interventions
Tapinarof Cream 1%, VTAMA®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
26
States / cities
Scottsdale, Arizona • Bryant, Arkansas • Dublin, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 23, 2026, 4:20 AM EDT
Completed Phase 2 Interventional Results available

Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers

NCT00941330
View directory record Official record
Conditions
Breast Cancer
Interventions
Exemestane, Docetaxel, Cytoxan
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 23, 2026, 4:20 AM EDT
Recruiting Early Phase 1 Interventional

Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH)

NCT07837830
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Treprostinil, Standard of Care
Drug · Other
Lead sponsor
Valley Health System
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 4:20 AM EDT
Completed Phase 2Phase 3 Interventional

Acupressure for Persistent Cancer Related Fatigue

NCT01281904
View directory record Official record
Conditions
Chronic Fatigue, Breast Cancer, Sleepiness
Interventions
Relaxation Acupressure, Stimulating Acupressure
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Oct 23, 2026, 4:20 AM EDT
Completed Phase 2 Interventional Results available

Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris

NCT00673933
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Methyl aminolevulinate (MAL) PDT
Drug
Lead sponsor
Photocure
Industry
Eligibility
15 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Naperville, Illinois • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Oct 23, 2026, 4:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

Autologous Adipose Cells Therapy

NCT06869252
View directory record Official record
Conditions
Hair Loss/Baldness, Wrinkle Appearance, Volume, Fine Lines, Skin Elasticity, Hair Thinning, Skin Pigmentation, Skin Texture
Interventions
Autologous Adipose Cells Therapy
Biological
Lead sponsor
CERM INC.
Industry
Eligibility
21 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Lewes, Delaware • Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 23, 2026, 4:20 AM EDT
Terminated Phase 2 Interventional Results available

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

NCT00302952
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lovastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 23, 2026, 4:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Genetic Determinants of Eczema Herpeticum and Other Viral Infections in Individuals With Atopic Dermatitis

NCT00515047
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Months to 80 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
7
States / cities
La Jolla, California • Denver, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 23, 2026, 4:20 AM EDT
Recruiting Phase 2 Interventional

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

NCT07685938
View directory record Official record
Conditions
Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer, Mediastinal Cancers, Spine Metastases, Spinal Tumor, Thoracic Cancer, Thoracic Neoplasms
Interventions
Atorvastatin and Lisinopril, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 23, 2026, 4:20 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma

NCT00004148
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
recombinant vaccinia-B7.1 vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 23, 2026, 4:20 AM EDT
Not listed Not applicable Interventional

Sebacia Postmarket Study of Real-World Use

NCT03818555
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Sebacia Microparticles Treatment
Other
Lead sponsor
Sebacia, Inc.
Industry
Eligibility
12 Years to 45 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Miami, Florida • Boston, Massachusetts • Murfreesboro, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 23, 2026, 4:20 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

NCT00243685
View directory record Official record
Conditions
Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma, Soft Tissue
Interventions
Laboratory Assay, Mick Assay
Other
Lead sponsor
Pierian Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 23, 2026, 4:20 AM EDT
Completed No phase listed Observational

A Non-drug Study Profiling Cutaneous Lupus

NCT01923415
View directory record Official record
Conditions
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid
Interventions
No intervention, skin biopsy, No intervention, blood collection, No intervention, urine collection
Procedure
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Indianapolis, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 23, 2026, 4:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Steroid Hormones, TH1/TH2 Cytokines and Reproductive Status

NCT00001376
View directory record Official record
Conditions
Arthritis, Rheumatoid, Healthy, Pregnancy
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 4:20 AM EDT
Active, not recruiting Phase 2 Interventional

Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts

NCT07806617
View directory record Official record
Conditions
Warts, Verruca (Warts), Verruca Vulgaris
Interventions
9-valent human papillomavirus vaccine, Sterile Saline
Biological · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 4:20 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

NCT06564389
View directory record Official record
Conditions
Healthy Participants, Atopic Dermatitis
Interventions
PF-07832837, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
5
States / cities
Anaheim, California • San Diego, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 4:20 AM EDT
Completed Phase 3 Interventional

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

NCT00014391
View directory record Official record
Conditions
Cancer
Interventions
palivizumab, ribavirin
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 23, 2026, 4:20 AM EDT
Active, not recruiting No phase listed Observational

Database Retrieval for the Comprehensive Shoulder

NCT03409718
View directory record Official record
Conditions
Osteoarthritis of the Shoulder, Avascular Necrosis, Rheumatoid Arthritis, Prior Failed Revision, Correction of Functional Deformity, Fracture of Proximal End of Humerus, Cuff Tear Arthropathy
Interventions
Biomet Comprehensive Shoulder System
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 23, 2026, 4:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors

NCT03304587
View directory record Official record
Conditions
Breast Cancer
Interventions
Polysomnography (PSG), Rectal thermistor 400 Series, Bright blue-green light, Dim red light, Digital foot candle datalogging light meter, Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue, Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance, Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression, Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function, Pittsburgh Sleep Quality Index (PSQI), Center for Epidemiological Studies - Depression, Montreal Cognitive Assessment (MoCA), European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30), Daily Log
Diagnostic Test · Other
Lead sponsor
Michigan State University
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 23, 2026, 4:20 AM EDT
Completed Phase 2 Interventional Results available

Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata

NCT03551821
View directory record Official record
Conditions
Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions
ATI-50002
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 23, 2026, 4:20 AM EDT
Completed Phase 2 Interventional

Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo

NCT03123016
View directory record Official record
Conditions
Vitiligo
Interventions
Apremilast, NB-UVB phototherapy
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 23, 2026, 4:20 AM EDT